- Home
- MP vs PTCT Comparison
MP vs PTCT Comparison
Compare MP & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- PTCT
- Stock Information
- Founded
- MP 2017
- PTCT 1998
- Country
- MP United States
- PTCT United States
- Employees
- MP N/A
- PTCT N/A
- Industry
- MP Metal Mining
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- MP Basic Materials
- PTCT Health Care
- Exchange
- MP Nasdaq
- PTCT Nasdaq
- Market Cap
- MP 4.0B
- PTCT 3.7B
- IPO Year
- MP N/A
- PTCT 2013
- Fundamental
- Price
- MP $37.70
- PTCT $50.34
- Analyst Decision
- MP Buy
- PTCT Buy
- Analyst Count
- MP 9
- PTCT 14
- Target Price
- MP $27.06
- PTCT $63.57
- AVG Volume (30 Days)
- MP 13.0M
- PTCT 1.1M
- Earning Date
- MP 07-31-2025
- PTCT 08-07-2025
- Dividend Yield
- MP N/A
- PTCT N/A
- EPS Growth
- MP N/A
- PTCT N/A
- EPS
- MP N/A
- PTCT 7.51
- Revenue
- MP $215,981,000.00
- PTCT $1,772,758,000.00
- Revenue This Year
- MP $23.82
- PTCT $121.50
- Revenue Next Year
- MP $88.68
- PTCT N/A
- P/E Ratio
- MP N/A
- PTCT $6.68
- Revenue Growth
- MP 4.63
- PTCT 91.12
- 52 Week Low
- MP $10.02
- PTCT $28.72
- 52 Week High
- MP $39.10
- PTCT $58.38
- Technical
- Relative Strength Index (RSI)
- MP 79.51
- PTCT 54.78
- Support Level
- MP $23.26
- PTCT $49.47
- Resistance Level
- MP $39.10
- PTCT $52.45
- Average True Range (ATR)
- MP 2.74
- PTCT 1.54
- MACD
- MP 1.54
- PTCT -0.09
- Stochastic Oscillator
- MP 92.63
- PTCT 49.17
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.